TY - T1的血管性帕金森症的临床特征病理确诊病例(P06.074) JF -神经学乔-神经病学SP - P06.074 LP - P06.074六世- 78 - 1补充AU -菲利普·格拉斯AU -安德鲁。李盟首页Aroldo Bacellar AU - Jan Zijlmans盟Regina Katzenschlager AU -劳拉Silveira-Moriyama Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/P06.074.abstract N2 -目的:评估详细临床特征在一个大的系列病理确诊病例血管震颤麻痹(VP)。背景仍然是一个定义糟糕的副总裁二实体。没有被广泛接受的诊断标准,病理证实诊断是至关重要的,以确保诊断的可靠性,而且只能在一些小系列。设计/方法:女王广场的档案记录大脑银行(QSBB)用于标识例帕金森氏综合征,脑血管疾病被认为是唯一的病理原因。临床记录审查和里程碑的疾病进展与其他parkinosonian综合症从先前QSBB系列。结果:28例包括在内。平均发病年龄为70.6 (SD±6.42)年,意味着疾病持续时间是10.5 (SD±6.1)年。血管危险因素出现在88%的患者中,刚度在96%,动作迟缓的88%,下降76%,锥体迹象在54%,39%,尿失禁,50%的痴呆症。三分之二有一个阴险的发病和稳定,而不是逐步发展的障碍。20(76.9%)有一个持续的对左旋多巴的回应。没有一个病人视觉幻觉。一个案例中,异常的多巴胺转运体(DAT) SPECT扫描。 Milestones of disease progression were closely linked with the age of onset of disease and when compared with other parkinosonian syndromes, VP had an older age of onset than PSP, MSA and PD.Conclusions: Scrutiny of the clinical case notes revealed a bradykinetic rigid syndrome of late onset with a high frequency of vascular risk factors. New findings included the absence of visual hallucinations and a high frequency of non-motor symptoms in patients with VP. The finding of an abnormal DAT suggests that in clinical practice an abnormal result does exclude the diagnosis of vascular parkinsonism.Supported by: Reta Lila Weston Institute of Neurological Studies.Disclosure: Dr. Glass has nothing to disclose. Dr. Lees has received personal compensation for activities with Genus, Novartis, Teva, Meda, Boehringer Ingelheim, GlaxoSmithKline, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira and Roche. Dr. Lees has received research support from the PSP Association and Weston Trust - The Reta Lila Howard Foundation. Dr. Bacellar has nothing to disclose. Dr. Zijlmans has nothing to disclose. Dr. Katzenschlager has received personal compensation for activities with GlaxoSmithKline, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., UCB Pharma, Cephalon, Abbott Laboratories, Inc., Novartis, and Lundbeck Research USA, Inc. as a speaker and/or advisor. Dr. Silveira-Moriyama has received personal compensation for activities with Teva Lundabeck. Dr. Silveira-Moiryama has received research support from Parkin Parkinson's UK, UCB, Genus, and Abbott.Thursday, April 26 2012, 07:30 am-12:00 pm ER -